Share This Activity
Subject: I'd like to recommend this activity on


Conversations in HCV: Evolving Treatment Options
Certified CME/CNE/CPE Activity

New pan-genotypic regimens continue to transform HCV management with more potent, more convenient, and safer regimens. These rapid changes require clinicians to become continually educated on the state-of-the-art approach to HCV management as well as safe and appropriate use of these newer regimens.

These Conversations in HCV will discuss the use of 8- or 12-week HCV regimens in treatment-naïve patients, HCV management issue in contemporary difficult-to-cure patients, and considerations in the setting of renal disease, HCC, and transplantation.
Review each video to claim AMA, ANCC, or ACPE credit/contact hour(s) after completion of the brief Post-Test/Evaluation.

Ask the Expert
Robert S. Brown, Jr., MD, MPH Robert S. Brown, Jr., MD, MPH
Gladys and Roland Harriman
Professor of Medicine
Clinical Chief, Division of Gastroenterology & Hepatology
Weill Cornell Medical College
Director, Center for Liver Disease and Transplantation
New York-Presbyterian Hospital
David Nelson, MD David Nelson, MD
Professor of Medicine and
Assistant Vice President for Research
University of Florida
Nancy Reau, MD, FAASLD, AGAF Nancy Reau, MD, FAASLD, AGAF
Section Chief, Hepatology
Rush University Medical Center
Associate Director, Solid Organ Transplantation
Rush University Medical Center

Please review the required information below (use scroll bar on the right)
and then click the
"Access Activity"
button to access this activity.


Conversation in HCV will discuss the evolving management and treatment issues such as 8 v. 12 weeks in treatment naïve patients, difficult‐to‐treat patients, advanced liver and kidney issues and HCC in HCV.

Release Date: February 8, 2018
Expiration Date: January 31, 2019


This activity is intended for physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat/manage patients with hepatitis C.


Upon completion of this enduring material, participants should be able to:


    • There are no fees for participating in and receiving credit for this activity.
    • Review the activity objectives and CME/CE information.
    • Review all modules associated with this course.
    • Successfully complete the post-test ( accuracy).
    • Complete the CME/CE evaluation.
    • The estimated time to complete this activity is hour.
    • Upon successful completion, your CME/CNE certificate will be emailed to you. CPE credit will be submitted to the Rush University Medical Center and posted to CPE Monitor.


    Rush Logo

    Joint accred logo

    In support of improving patient care, Rush University Medical Center is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

    Rush University Medical Center designates this live activity for a maximum of AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    ANCC Credit Designation – Nurses
    The maximum number of hours awarded for this CE activity is contact hours.

    Rush University Medical Center designates this knowledge-based CPE activity (UAN # ) for contact hours for pharmacists.

    Participation in the entire knowledge-based activity is required to obtain a certificate. This activity is being presented without bias and with commercial support.


    In accordance with the ACCME Standards for Commercial Support of CME, the Rush University Medical Center and Practice Point Communications will implement mechanisms, prior to the planning and implementation of this CME/CE activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME/CE activity.


    All planners and faculty participating in continuing education activities provided by the Rush University Medical Center are expected to disclose to the audience any support or relationship(s) with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. A commercial interest is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentation. The planners and faculty have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

    All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the Rush University Medical Center.

    The following indicates the disclosure declaration information and the nature of those commercial relationships.


    The speakers and planning committee members listed below have stated they have no significant relationships to disclose.
    Mary Grantner
    Chris Fleming
    Jill Valone

    The following speakers and/or planners have stated that they have the following financial relationship(s) and they have agreed to see that all information they planned and/or present is done so fairly and without bias:


    Robert S. Brown, Jr., MD, MPH
    Research grant from: Gilead Sciences
    Royalty: None
    Stockholder: None
    Member of Speaker’s Bureau: None
    Consultant to: AbbVie, Bristol-Myers Squibb, Intercept, Merck & Co., Shinogi
    Salary: N/A
    Other: None

    David Nelson, MD
    Research grant from: AbbVie, Gilead Sciences, Merck & Co.
    Royalty: None
    Stockholder: None
    Member of Speaker’s Bureau: None
    Consultant to: None Other: None
    Salary: N/A

    Nancy Reau, MD, FAASLD, AGAF
    Research grant from: None
    Royalty: None
    Stockholder: None
    Member of Speaker’s Bureau: None
    Consultant to: AbbVie, Gilead Sciences, Intercept, Merck & Co.
    Salary: N/A
    Other: None


    The Rush University Medical Center and Practice Point Communications present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The Rush University Medical Center, Practice Point Communications, and ViiV Healthcare assume no liability for the information herein.


    The Rush University Medical Center and Practice Point Communications protect the privacy of personal and other information regarding participants and educational collaborators. The Rush University Medical Center and Practice Point Communications will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME, ANCC, or ACPE.

    Rush University Medical Center and Practice Point Communications maintain physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information that we have collected from you.


    Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software (“Materials”) found on the site subject to the following terms, conditions, and exceptions:

    The Materials are to be used solely for personal, noncommercial, informational, and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.

    Materials may not be published, uploaded, posted, or transmitted (other than as set forth herein) without prior written permission.


    • Hardware: A minimum of 512MB of RAM and a Pentium IV CPU for Intel-based hardware & PowerPC G4 or above for MAC.
    • Graphics/Monitor: A color monitor capable of a minimum of 1024 x 768 pixel resolution.
    • Network: An Internet connection with 1Mbps available download & 256kbps bandwidth.
    • Windows 7 or above running Internet Explorer 10 or above.
    • MAC OSX 10.5 (Leopard) or above running Safari 6 or above, or any version of Chrome, Firefox or Opera published in the last two years.
    • A recent version of a Linux distribution or FreeBSD running Chrome v13, Opera 11.5, Firefox 5.0.1, or Epiphany 3.0.4 or above.
    Mobile Device:
    • Any Apple iPad or iPad Mini running iOS 7.1 or above.
    • Android tablets such as the Kindle Fire or Samsung Galaxy S.


    Supported by an independent educational grant from AbbVie and Gilead Sciences Medical Affairs. .

    Supported by an independent educational grant from AbbVie and Gilead Sciences Medical Affairs
    January 31, 2019
    Clinical Conversation
    HIV, Hepatitis, Liver Disease
    World AIDS Day Badge

    Upcoming Live Activities

    No upcoming live activities
    Copyright 2018 by Practice Point Communications